Royalty Pharma

Website Links

Description

Since our inception in 1996, Royalty Pharma has expanded the traditional parameters that define a pharmaceutical company. By focusing on intellectual property - the key to premium pricing and profits in the pharmaceutical industry - Royalty Pharma has become the global leader in the acquisition of royalty interests. Royalty Pharma has assembled a well diversified and well balanced portfolio of royalties in leading biopharmaceutical products achieving rapid and profitable growth with a managed risk profile. The origins of Royalty Pharma can be traced to the 1980s when certain members of Royalty Pharma’s Investment Committee and Management pioneered the use of royalty interests to fund the clinical development of several leading biotechnology products through “Research & Development Partnerships.” In 1993 and 1994, when these R&D partnerships started earning royalties, two product-specific "proof of principle" acquisition vehicles were established to acquire royalty interests in Neupogen

Products & services

Similar companies nearby